<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02235064</url>
  </required_header>
  <id_info>
    <org_study_id>CUH IRB#: 14-078</org_study_id>
    <nct_id>NCT02235064</nct_id>
  </id_info>
  <brief_title>Prophylactic Use of Postpartum Sertraline to Prevent Postpartum Depression</brief_title>
  <official_title>Prophylactic Use of Immediate Postpartum Sertraline to Prevent Postpartum Depression: A Double Blind Randomized Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cooper Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cooper Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to assess the effectiveness of preventative antidepressants
      immediately following delivery on postpartum depression rates in women at high risk due to
      prior history of depression or postpartum depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible women for our study would be identified antepartum from our three obstetrical groups
      delivering at Cooper University Hospital: Cooper Faculty Group, Women's Care Center, and
      CamCare. Potentially eligible women would be referred to the study coordinator or principal
      investigator to discuss the nature of the study. Those women who agreed to the trial would be
      further screened with a baseline structured psychiatric evaluation in the third trimester of
      the pregnancy to rule-out current depressive illness. If there was no evidence of depression
      at the antepartum evaluation, patients delivering a liveborn singleton fetus at 34 0/7 weeks
      or greater would be re-evaluated prior to discharge and, if scoring &lt;/= 12 on the Edinburgh
      Postpartum Depression scale, would then be enrolled in the trial.

      Patients would be assigned to either sertraline 50 mg daily or identical appearing placebo
      for 12 weeks. Group allocation would be determined by restricted-randomization technique with
      variable block length, with the sequence generated by someone not associated with participant
      assignment. Assignment would be kept in sequentially numbered, opaque, sealed envelopes
      (SNOSE) in the pharmacy, which would dispense the medication (or placebo). Patients would be
      given a 30 day supply on the day of discharge, with refills provided by the study coordinator
      (through the pharmacy)for 12 weeks and a four-day supply of 25 mg Sertraline or placebo at
      the end of 12 weeks as a taper. Patients would also undergo follow-up blinded structured
      psychiatric evaluations at 4 weeks, 8 weeks, and 12 weeks to assess for adverse reaction to
      the assigned treatment agent, and for administration of questionnaires/evaluation to assess
      for development of depression. Any patient with recognized clinical depression would
      immediately be removed from further active participation in the study and referred to our
      Cooper Psychiatry department or outside psychiatrist for ongoing evaluation and treatment.
      Medication received (Sertraline or Placebo) would necessarily be revealed to Psych only for
      purposes of guiding appropriate further treatment.

      All women randomized would be analyzed according to group assignment (intent-to-treat).
      Demographic information, including patient age, race/ethnicity, gravidity, parity,
      gestational age at delivery, infant birth weight, as well as infant weights from standard
      Pediatric visits (obtained verbally from the mother)would be recorded and compared using the
      Student t-test for normally distributed continuous data, Mann-Whitney U for non-normative
      continuous data, and the Chi Square test or Fisher Exact test for categorical data.

      A sample size calculation was performed. Based on an anticipated rate of postpartum
      depression (PPD) of 30% in the placebo group, we would need 62 subjects in each group to
      detect a reduction in PPD to 10% in the sertraline group, with a power of .8 and a Type I
      error of .05. Based on the 2200 deliveries occurring annually at Cooper University Hospital,
      we anticipate that it would take 2-3 years to recruit 124 subjects into this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low recruitment, completion of funding cycle
  </why_stopped>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Development of Postpartum Depression up to 12 Weeks Following Discharge From Hospital</measure>
    <time_frame>Discharge from hospital to 12 weeks postpartum</time_frame>
    <description>Patients met with single psychiatrist (co-investigator), blinded to group assignment, who evaluated the patient using Edinburgh Postpartum Depression Screen, Hamilton Depression Rating Scale, Global Assessment of Functioning Scale, and clinical assessment
0 = No postpartum depression up to 12 weeks following discharge from hospital
1 = Postpartum depression up to 12 weeks following discharge from hospital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Reaction to Treatment Agent up to 12 Weeks Following Discharge From Hospital</measure>
    <time_frame>Discharge from hospital to 12 weeks postpartum</time_frame>
    <description>The Antidepressant Side-Effect Checklist (ASEC) was employed to detect any adverse reaction to treatment regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reported Infant Weight at 4 Weeks Following Delivery</measure>
    <time_frame>4 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Perceived Infant Sleeping Difficulty at 4 Weeks Postpartum</measure>
    <time_frame>4 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Perceived Infant Feeding Difficulties 4 Weeks Postpartum</measure>
    <time_frame>4 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reported Infant Weight at 8 Weeks Following Delivery</measure>
    <time_frame>8 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reported Infant Weight at 12 Weeks Following Delivery</measure>
    <time_frame>12 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Perceived Infant Sleeping Difficulty at 8 Weeks Postpartum</measure>
    <time_frame>8 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Perceived Infant Sleeping Difficulty at 12 Weeks Postpartum</measure>
    <time_frame>12 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Perceived Infant Feeding Difficulties 8 Weeks Postpartum</measure>
    <time_frame>8 weeks postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Perceived Infant Feeding Difficulties 12 Weeks Postpartum</measure>
    <time_frame>12 weeks postpartum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Depression, Postpartum</condition>
  <arm_group>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical appearing capsule daily containing color-matched cellulose only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper</description>
    <arm_group_label>Sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule containing cellulose powder of same color as experimental arm</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cellulose powder</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Past history of depression or postpartum depression

          2. Singleton gestation

          3. Delivery &gt; 34 weeks gestation

          4. No current clinical evidence of depression

          5. Able to read and understand written English language

        Exclusion Criteria:

          1. Multiple gestation

          2. Delivery prior to 34 weeks

          3. Delivery outside of Cooper University Hospital

          4. Major fetal anomaly or fetal demise

          5. Current use of antidepressants

          6. Evidence of active depression at antepartum evaluation

          7. Edinburgh Postpartum Depression scale of &gt;12 prior to discharge from the hospital

          8. Maternal age &lt; 18 years

          9. Infant in Neonatal Intensive Care Unit (NICU) at time of patient discharge from
             hospital

         10. Known or suspected allergy to Sertraline
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard L Fischer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cooper Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006 Feb 9;354(6):579-87.</citation>
    <PMID>16467545</PMID>
  </reference>
  <reference>
    <citation>Gold LH. Postpartum disorders in primary care: diagnosis and treatment. Prim Care. 2002 Mar;29(1):27-41, vi. Review.</citation>
    <PMID>11856657</PMID>
  </reference>
  <reference>
    <citation>ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008 Apr;111(4):1001-20. doi: 10.1097/AOG.0b013e31816fd910. Review.</citation>
    <PMID>18378767</PMID>
  </reference>
  <reference>
    <citation>Howard LM, Hoffbrand S, Henshaw C, Boath L, Bradley E. Antidepressant prevention of postnatal depression. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004363. Review. Update in: Cochrane Database Syst Rev. 2018 Apr 18;4:CD004363.</citation>
    <PMID>15846711</PMID>
  </reference>
  <reference>
    <citation>Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005 Dec;106(6):1289-96.</citation>
    <PMID>16319254</PMID>
  </reference>
  <reference>
    <citation>Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA. 2005 May 18;293(19):2372-83. Review.</citation>
    <PMID>15900008</PMID>
  </reference>
  <reference>
    <citation>Payne JL. Antidepressant use in the postpartum period: practical considerations. Am J Psychiatry. 2007 Sep;164(9):1329-32. Review.</citation>
    <PMID>17728416</PMID>
  </reference>
  <reference>
    <citation>Pearlstein T, Howard M, Salisbury A, Zlotnick C. Postpartum depression. Am J Obstet Gynecol. 2009 Apr;200(4):357-64. doi: 10.1016/j.ajog.2008.11.033. Review.</citation>
    <PMID>19318144</PMID>
  </reference>
  <reference>
    <citation>Safety of SSRIs in Pregnancy. Med Lett Drugs Ther. 2008 Nov 17;50(1299):89-91. Review.</citation>
    <PMID>19008787</PMID>
  </reference>
  <reference>
    <citation>Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005 Feb 5-11;365(9458):482-7.</citation>
    <PMID>15705457</PMID>
  </reference>
  <reference>
    <citation>Wisner KL, Perel JM, Peindl KS, Hanusa BH, Piontek CM, Findling RL. Prevention of postpartum depression: a pilot randomized clinical trial. Am J Psychiatry. 2004 Jul;161(7):1290-2.</citation>
    <PMID>15229064</PMID>
  </reference>
  <reference>
    <citation>Wisner KL, Perel JM, Peindl KS, Hanusa BH, Findling RL, Rapport D. Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatry. 2001 Feb;62(2):82-6.</citation>
    <PMID>11247106</PMID>
  </reference>
  <reference>
    <citation>Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol. 2009 Sep;114(3):703-13. doi: 10.1097/AOG.0b013e3181ba0632. Review.</citation>
    <PMID>19701065</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2014</study_first_submitted>
  <study_first_submitted_qc>September 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2014</study_first_posted>
  <results_first_submitted>February 24, 2017</results_first_submitted>
  <results_first_submitted_qc>February 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 10, 2017</results_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cooper Health System</investigator_affiliation>
    <investigator_full_name>Richard Fischer MD</investigator_full_name>
    <investigator_title>Professor, Department of OB/GYN, Cooper Medical School of Rowan University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression, Postpartum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only aggregate data to be reported</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sertraline</title>
          <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper
Sertraline: Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Identical appearing capsule daily containing color-matched cellulose only
Placebo: Capsule containing cellulose powder of same color as experimental arm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sertraline</title>
          <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper
Sertraline: Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Identical appearing capsule daily containing color-matched cellulose only
Placebo: Capsule containing cellulose powder of same color as experimental arm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="33" upper_limit="33"/>
                    <measurement group_id="B2" value="30" lower_limit="30" upper_limit="30"/>
                    <measurement group_id="B3" value="31.5" lower_limit="30" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Development of Postpartum Depression up to 12 Weeks Following Discharge From Hospital</title>
        <description>Patients met with single psychiatrist (co-investigator), blinded to group assignment, who evaluated the patient using Edinburgh Postpartum Depression Screen, Hamilton Depression Rating Scale, Global Assessment of Functioning Scale, and clinical assessment
0 = No postpartum depression up to 12 weeks following discharge from hospital
1 = Postpartum depression up to 12 weeks following discharge from hospital</description>
        <time_frame>Discharge from hospital to 12 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper
Sertraline: Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical appearing capsule daily containing color-matched cellulose only
Placebo: Capsule containing cellulose powder of same color as experimental arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Development of Postpartum Depression up to 12 Weeks Following Discharge From Hospital</title>
          <description>Patients met with single psychiatrist (co-investigator), blinded to group assignment, who evaluated the patient using Edinburgh Postpartum Depression Screen, Hamilton Depression Rating Scale, Global Assessment of Functioning Scale, and clinical assessment
0 = No postpartum depression up to 12 weeks following discharge from hospital
1 = Postpartum depression up to 12 weeks following discharge from hospital</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Reaction to Treatment Agent up to 12 Weeks Following Discharge From Hospital</title>
        <description>The Antidepressant Side-Effect Checklist (ASEC) was employed to detect any adverse reaction to treatment regimens</description>
        <time_frame>Discharge from hospital to 12 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical appearing capsule daily containing color-matched cellulose only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Reaction to Treatment Agent up to 12 Weeks Following Discharge From Hospital</title>
          <description>The Antidepressant Side-Effect Checklist (ASEC) was employed to detect any adverse reaction to treatment regimens</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reported Infant Weight at 4 Weeks Following Delivery</title>
        <time_frame>4 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical appearing capsule daily containing color-matched cellulose only</description>
          </group>
        </group_list>
        <measure>
          <title>Reported Infant Weight at 4 Weeks Following Delivery</title>
          <units>Grams</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3033" lower_limit="3033" upper_limit="3033"/>
                    <measurement group_id="O2" value="2750" lower_limit="2750" upper_limit="2750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Perceived Infant Sleeping Difficulty at 4 Weeks Postpartum</title>
        <time_frame>4 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical appearing capsule daily containing color-matched cellulose only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Perceived Infant Sleeping Difficulty at 4 Weeks Postpartum</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Perceived Infant Feeding Difficulties 4 Weeks Postpartum</title>
        <time_frame>4 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical appearing capsule daily containing color-matched cellulose only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Perceived Infant Feeding Difficulties 4 Weeks Postpartum</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reported Infant Weight at 8 Weeks Following Delivery</title>
        <time_frame>8 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical appearing capsule daily containing color-matched cellulose only</description>
          </group>
        </group_list>
        <measure>
          <title>Reported Infant Weight at 8 Weeks Following Delivery</title>
          <units>Grams</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5301" lower_limit="5301" upper_limit="5301"/>
                    <measurement group_id="O2" value="3685" lower_limit="3685" upper_limit="3685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reported Infant Weight at 12 Weeks Following Delivery</title>
        <time_frame>12 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical appearing capsule daily containing color-matched cellulose only</description>
          </group>
        </group_list>
        <measure>
          <title>Reported Infant Weight at 12 Weeks Following Delivery</title>
          <units>Grams</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5301" lower_limit="5301" upper_limit="5301"/>
                    <measurement group_id="O2" value="4734" lower_limit="4734" upper_limit="4734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Perceived Infant Sleeping Difficulty at 8 Weeks Postpartum</title>
        <time_frame>8 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical appearing capsule daily containing color-matched cellulose only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Perceived Infant Sleeping Difficulty at 8 Weeks Postpartum</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Perceived Infant Sleeping Difficulty at 12 Weeks Postpartum</title>
        <time_frame>12 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical appearing capsule daily containing color-matched cellulose only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Perceived Infant Sleeping Difficulty at 12 Weeks Postpartum</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Perceived Infant Feeding Difficulties 8 Weeks Postpartum</title>
        <time_frame>8 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical appearing capsule daily containing color-matched cellulose only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Perceived Infant Feeding Difficulties 8 Weeks Postpartum</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Perceived Infant Feeding Difficulties 12 Weeks Postpartum</title>
        <time_frame>12 weeks postpartum</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical appearing capsule daily containing color-matched cellulose only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Perceived Infant Feeding Difficulties 12 Weeks Postpartum</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sertraline</title>
          <description>Capsules containing crushed sertraline 50 mg combined with identically colored cellulose, daily for 12 weeks, followed by 4 day 25 mg taper
Sertraline: Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Identical appearing capsule daily containing color-matched cellulose only
Placebo: Capsule containing cellulose powder of same color as experimental arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard L Fischer</name_or_title>
      <organization>Cooper University Health System</organization>
      <phone>856-342-2491</phone>
      <email>fischer-richard@cooperhealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

